These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 32211339)

  • 1. N-Glycans Mediate the Ebola Virus-GP1 Shielding of Ligands to Immune Receptors and Immune Evasion.
    Iraqi M; Edri A; Greenshpan Y; Kundu K; Bolel P; Cahana A; Ottolenghi A; Gazit R; Lobel L; Braiman A; Porgador A
    Front Cell Infect Microbiol; 2020; 10():48. PubMed ID: 32211339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive functional analysis of N-linked glycans on Ebola virus GP1.
    Lennemann NJ; Rhein BA; Ndungo E; Chandran K; Qiu X; Maury W
    mBio; 2014 Jan; 5(1):e00862-13. PubMed ID: 24473128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting host O-linked glycan biosynthesis affects Ebola virus replication efficiency and reveals differential GalNAc-T acceptor site preferences on the Ebola virus glycoprotein.
    Bagdonaite I; Abdurahman S; Mirandola M; Pasqual D; Frank M; Narimatsu Y; Joshi HJ; Vakhrushev SY; Salata C; Mirazimi A; Wandall HH
    J Virol; 2024 Jun; 98(6):e0052424. PubMed ID: 38757972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steric shielding of surface epitopes and impaired immune recognition induced by the ebola virus glycoprotein.
    Francica JR; Varela-Rohena A; Medvec A; Plesa G; Riley JL; Bates P
    PLoS Pathog; 2010 Sep; 6(9):e1001098. PubMed ID: 20844579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MARCH8 Inhibits Ebola Virus Glycoprotein, Human Immunodeficiency Virus Type 1 Envelope Glycoprotein, and Avian Influenza Virus H5N1 Hemagglutinin Maturation.
    Yu C; Li S; Zhang X; Khan I; Ahmad I; Zhou Y; Li S; Shi J; Wang Y; Zheng YH
    mBio; 2020 Sep; 11(5):. PubMed ID: 32934085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of ebola virus GP DNA vaccines.
    Dowling W; Thompson E; Badger C; Mellquist JL; Garrison AR; Smith JM; Paragas J; Hogan RJ; Schmaljohn C
    J Virol; 2007 Feb; 81(4):1821-37. PubMed ID: 17151111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Tetherin Antagonism of the Ebola Virus Glycoprotein Requires an Intact Receptor-Binding Domain and Can Be Blocked by GP1-Specific Antibodies.
    Brinkmann C; Nehlmeier I; Walendy-Gnirß K; Nehls J; González Hernández M; Hoffmann M; Qiu X; Takada A; Schindler M; Pöhlmann S
    J Virol; 2016 Dec; 90(24):11075-11086. PubMed ID: 27707924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucin-Like Domain of Ebola Virus Glycoprotein Enhances Selective Oncolytic Actions against Brain Tumors.
    Zhang X; Zhang T; Davis JN; Marzi A; Marchese AM; Robek MD; van den Pol AN
    J Virol; 2020 Mar; 94(8):. PubMed ID: 32051271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Conserved N-Linked Glycans on Ebola Virus Glycoprotein 2.
    Lennemann NJ; Walkner M; Berkebile AR; Patel N; Maury W
    J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S204-9. PubMed ID: 26038399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of Ebola Virus Infection via Ficolin-1 Interaction with the Mucin Domain of GP Glycoprotein.
    Favier AL; Gout E; Reynard O; Ferraris O; Kleman JP; Volchkov V; Peyrefitte C; Thielens NM
    J Virol; 2016 Jun; 90(11):5256-5269. PubMed ID: 26984723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycan shield of the ebolavirus envelope glycoprotein GP.
    Peng W; Rayaprolu V; Parvate AD; Pronker MF; Hui S; Parekh D; Shaffer K; Yu X; Saphire EO; Snijder J
    Commun Biol; 2022 Aug; 5(1):785. PubMed ID: 35927436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Perspectives on Ebola Virus Evolution.
    Brown CJ; Quates CJ; Mirabzadeh CA; Miller CR; Wichman HA; Miura TA; Ytreberg FM
    PLoS One; 2016; 11(8):e0160410. PubMed ID: 27479005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The signal peptide of the ebolavirus glycoprotein influences interaction with the cellular lectins DC-SIGN and DC-SIGNR.
    Marzi A; Akhavan A; Simmons G; Gramberg T; Hofmann H; Bates P; Lingappa VR; Pöhlmann S
    J Virol; 2006 Jul; 80(13):6305-17. PubMed ID: 16775318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antigenic subversion: a novel mechanism of host immune evasion by Ebola virus.
    Mohan GS; Li W; Ye L; Compans RW; Yang C
    PLoS Pathog; 2012; 8(12):e1003065. PubMed ID: 23271969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Ebola-Glycoprotein Modulates the Function of Natural Killer Cells.
    Edri A; Shemesh A; Iraqi M; Matalon O; Brusilovsky M; Hadad U; Radinsky O; Gershoni-Yahalom O; Dye JM; Mandelboim O; Barda-Saad M; Lobel L; Porgador A
    Front Immunol; 2018; 9():1428. PubMed ID: 30013549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice.
    Bengtsson KL; Song H; Stertman L; Liu Y; Flyer DC; Massare MJ; Xu RH; Zhou B; Lu H; Kwilas SA; Hahn TJ; Kpamegan E; Hooper J; Carrion R; Glenn G; Smith G
    Vaccine; 2016 Apr; 34(16):1927-35. PubMed ID: 26921779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge.
    Konduru K; Shurtleff AC; Bradfute SB; Nakamura S; Bavari S; Kaplan G
    PLoS One; 2016; 11(9):e0162446. PubMed ID: 27622456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Roles of Ebola Virus Soluble Glycoprotein in Replication, Pathogenesis, and Countermeasure Development.
    Zhu W; Banadyga L; Emeterio K; Wong G; Qiu X
    Viruses; 2019 Oct; 11(11):. PubMed ID: 31683550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
    Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907
    [No Abstract]   [Full Text] [Related]  

  • 20. Impact of Ebola mucin-like domain on antiglycoprotein antibody responses induced by Ebola virus-like particles.
    Martinez O; Tantral L; Mulherkar N; Chandran K; Basler CF
    J Infect Dis; 2011 Nov; 204 Suppl 3(Suppl 3):S825-32. PubMed ID: 21987758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.